The Fab and F(ab')2 fragments are capable of targeting CAIX in hypoxic regions at shorter time periods post-injection, but this comes at the cost of reduced absolute uptake and severely reduced tumor to muscle ratios. The gene discussed is CA9; the disease is neoplasm.